2010-06-16
THE EFFICACY OF TELMISARTAN IN THE METABOLIC SYNDROME
General Medicine
The Metabolic Syndrome is a clinical condition characterized by the presence of multiple cardiovascular risk factors in the same subject, and particularly, hypertension and insulin resistance.
Telmisartan is an antihypertensive agent with partial activity on peroxisome proliferator-activated gamma receptor (PPAR-y) and is able to improve insulin sensitivity and lipid profile in patients with Metabolic Syndrome. A study of the metabolic effect of telmisartan and losartan in patients with hypertension associated with Metabolic Syndrome has been carried out.
In this randomized and double blind study, patients with Metabolic Syndrome were treated with a daily dose of telmisartan (80 mg) or Losartan (50 mg) for a period of 3 months.
Patients were treated in groups of twenty: at the beginning and at the end of their treatment, fasting and post-prandial plasma glucose, sensitivity to insulin, glycosylated hemoglobin, and median systolic and diastolic blood pressure over 24 hours were measured.
Unlike losartan, telmisartan has been shown capable of significantly reducing (p less than 0.05), plasma glucose values, insulin resistance as well as glycosylated hemoglobin; results on lowering blood pressure were also superior with telmisartan.
In conclusion, this study has confirmed and corroborated the capacity of telmisartan to not only control the average blood pressure over 24 hours, but also to be capable of insulin-sensitizer activity, which can be explained by its partial activity on PPAR-y.
REFERENCES:
Cardiovascular Diabetology May 2005, 4:6
Metabolic effect of telmisartan and losartan in hypertensive patients with Metabolic Syndrome
Vitale, Mercury, Castiglioni, Cornoldi Tullio, Fini Volterrani and Rosano
Luca Gabriele Punziano
General Practitioner Specializing in Preventive Medicine and Hygiene, Umberto I Hospital, Rome, Italy
General Medicine
2010-06-16
The Metabolic Syndrome is a clinical condition characterized by the presence of multiple cardiovascular risk factors in the same subject, and particularly, hypertension and insulin resistance.
Telmisartan is an antihypertensive agent with partial activity on peroxisome proliferator-activated gamma receptor (PPAR-y) and is able to improve insulin sensitivity and lipid profile in patients with...
read
General Medicine
2010-05-26
Liver tumors, benign and malignant, primary and secondary, can cause hemoperitoneum, due to a minor thoraco-abdominal trauma only in very rare cases (1, 2).
CT angiography with contrast is the method most widely used as emergency diagnostic test. Its accuracy allows a better therapeutic management with increased survival rates. It provides essential information concerning the extent and...
read
General Medicine
2010-03-22
The A/H1N1 pandemic influenza has set in motion several strategies for healthcare related planning. Epidemiology, with its load of scientific knowledge related to Infection, vaccination and organization, has permitted to draw out possible scenarios, as well as strategies of attack and containment of an infection that had appeared to potentially be the most serious pandemic of the new century....
read
General Medicine
2010-02-09
Pregnancy is always a fascinating event in the life of the woman, of the couple, and of the environment around them, becoming an experience that is not only physical and biological, but that also extends to the mental, emotional and intellectual spheres.
Its physiological course can be compromised by preexisting diseases, diagnosed before the pregnancy or occurring during its course.
This is...
read
General Medicine
2009-12-11
Physical activity in patients with diabetes mellitus type 1 and type 2 is an important item in the treatment of both diseases. Diabetic patients should engage in regular physical activity, mostly aerobic. Physical activity should be practiced for at least 3-4 times a week, and for at least 30 to 40 minutes at a time, because it has been shown that the benefit of a single training session lasts...
read
